Deutsche Biotech Innovativ AG Stock Deutsche Boerse AG

Deutsche Biotech Innovativ AG, formerly Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The Company's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.